A detailed history of Schonfeld Strategic Advisors LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 122,782 shares of MGNX stock, worth $478,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,782
Holding current value
$478,849
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.31 - $18.51 $406,408 - $2.27 Million
122,782 New
122,782 $521,000
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $341,582 - $770,847
76,246 New
76,246 $733,000
Q3 2022

Nov 14, 2022

SELL
$3.01 - $5.22 $140,868 - $244,296
-46,800 Reduced 42.78%
62,600 $216,000
Q2 2022

Aug 15, 2022

BUY
$2.25 - $9.99 $226,800 - $1.01 Million
100,800 Added 1172.09%
109,400 $323,000
Q2 2021

Aug 16, 2021

BUY
$20.49 - $35.63 $176,214 - $306,418
8,600 New
8,600 $231,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $240M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.